ERBB2 and breast carcinoma: Recently, a first-in-human study evaluating the anti-HER2 DARPin tracer 99mTc-(HE)3-G3 for SPECT imaging of breast cancer reported a favorable safety and tolerability profile, and it showed clear visualization of both primary and metastatic HER2-positive lesions (NCT04277338) [41].